The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Pickering, T. G., Hall, J. E., Appel, L. J., Falkner, B. E., Graves, J., Hill, M. N., Jones, D. W., Kurtz, T., Sheps, S. G., & Roccella, E. J. (2005) · Circulation · doi:10.1161/01.cir.0000154900.76284.f6 · Cited by 3,985
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Causes and Prevalence of Visual Impairment Among Adults in the UnitedStates
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.477 · Cited by 2,616
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Cited by
Age-related macular degeneration
Mitchell, P., Liew, G., Gopinath, B., & Wong, T. Y. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31550-2 · Cited by 1,511
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Self-citationFERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
SPAIDE, R. F., LAUD, K., FINE, H. F., KLANCNIK, J. M., MEYERLE, C. B., YANNUZZI, L. A., SORENSON, J., SLAKTER, J., FISHER, Y. L., & COONEY, M. J. (2006) · Retina · doi:10.1097/00006982-200604000-00001 · Cited by 630
Optical coherence tomography: a review of clinical development from bench to bedside
Zysk, A. M., Nguyen, F. T., Oldenburg, A. L., Marks, D. L., & Boppart, S. A. (2007) · Journal of Biomedical Optics · doi:10.1117/1.2793736 · Cited by 547
Fung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Self-citationRICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
Self-citationITURRALDE, D., SPAIDE, R. F., MEYERLE, C. B., KLANCNIK, J. M., YANNUZZI, L. A., FISHER, Y. L., SORENSON, J., SLAKTER, J. S., FREUND, K. B., COONEY, M., et al. (2006) · Retina · doi:10.1097/00006982-200603000-00005 · Cited by 460
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
“A mild transient, but significant elevation in mean systolic blood pressure was reported in patients with CNV secondary to ARMD who received a systemic infusion of bevacizumab [9].”
BackgroundINTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA
HARITOGLOU, C., KOOK, D., NEUBAUER, A., WOLF, A., PRIGLINGER, S., STRAUSS, R., GANDORFER, A., ULBIG, M., & KAMPIK, A. (2006) · Retina · doi:10.1097/01.iae.0000247165.38655.bf · Cited by 453
Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans
Krohne, T. U., Eter, N., Holz, F. G., & Meyer, C. H. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.036 · Cited by 363
SHAHAR, J., AVERY, R. L., HEILWEIL, G., BARAK, A., ZEMEL, E., LEWIS, G. P., JOHNSON, P. T., FISHER, S. K., PERLMAN, I., & LOEWENSTEIN, A. (2006) · Retina · doi:10.1097/00006982-200603000-00002 · Cited by 350
Age-Related Macular Degeneration Preferred Practice Pattern®
Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A., Lim, J. I., Vemulakonda, G. A., & Ying, G.-S. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.09.024 · Cited by 349
Recent developments in optical coherence tomography for imaging the retina
van Velthoven, M. E. J., Faber, D. J., Verbraak, F. D., van Leeuwen, T. G., & de Smet, M. D. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2006.10.002 · Cited by 343
Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema
Arevalo, J. F., Fromow-Guerra, J., Quiroz-Mercado, H., Sanchez, J. G., Wu, L., Maia, M., Berrocal, M. H., Solis-Vivanco, A., & Farah, M. E. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.12.028 · Cited by 335
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Bashshur, Z. F., Bazarbachi, A., Schakal, A., Haddad, Z. A., El Haibi, C. P., & Noureddin, B. N. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.02.037 · Cited by 305
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ohc.2006.05.009 · Cited by 299
Transplantation of the RPE in AMD
Binder, S., Stanzel, B. V., Krebs, I., & Glittenberg, C. (2007) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2007.02.002 · Cited by 292
A review of clinical trials of anti-VEGF agents for diabetic retinopathy
Nicholson, B. P., & Schachat, A. P. (2010) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1315-z · Cited by 272
Mehta, H., Tufail, A., Daien, V., Lee, A. Y., Nguyen, V., Ozturk, M., Barthelmes, D., & Gillies, M. C. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.12.002 · Cited by 265
Sohn, H. J., Han, D. H., Kim, I. T., Oh, I. K., Kim, K. H., Lee, D. Y., & Nam, D. H. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.03.033 · Cited by 265
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR PERSISTENT NEW VESSELS IN DIABETIC RETINOPATHY (IBEPE STUDY)
JORGE, R., COSTA, R. A., CALUCCI, D., CINTRA, L. P., & SCOTT, I. U. (2006) · Retina · doi:10.1097/01.iae.0000246884.76018.63 · Cited by 258
INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Penetration of Bevacizumab through the Retina after Intravitreal Injection in the Monkey
Heiduschka, P., Fietz, H., Hofmeister, S., Schultheiss, S., Mack, A. F., Peters, S., Ziemssen, F., Niggemann, B., Julien, S., Bartz-Schmidt, K. U., et al. (2007) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-1171 · Cited by 253
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Dietary ω-3 Fatty Acid and Fish Intake and Incident Age-Related Macular Degeneration in Women
Christen, W. G. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.34 · Cited by 138
Olsen, T. W., Feng, X., Wabner, K., Csaky, K., Pambuccian, S., & Cameron, J. D. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6291 · Cited by 106
Klettner, A., & Roider, J. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1139-x · Cited by 74
Sterile Intraocular Inflammation After Intravitreal Injection—Diagnosis and Management
Greenberg, J. P., Peiris, T. J., & Lieberman, R. M. (2019) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2019.04.010 · Cited by 4
Metadata
- Authors
- MICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A.
- Venue
- Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2005-06
- Volume
- 112
- Issue
- 6
- Pages
- 1035-1047.e9
- ISSN
- 0161-6420 (ISSN-L)
- OpenAlex
- W2058775052
- Cited by
- 664
- References
- 60
- FWCI
- 68.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.